Moleculin is a clinical-stage pharmaceutical company advancing a new therapeutic approach to inflammatory and proliferative skin diseases, including psoriasis, atopic dermatitis, actinic keratosis, and skin cancers.
The topically administered drug candidates we have under investigation were designed to differentially block key oncogenic transcription factors—the cell signaling proteins known to play critical roles in promoting inflammatory and proliferative diseases. This constitutes an important new approach to the fight against chronic skin diseases. Our lead product candidate, MOL4249, which has demonstrated an ability to block the activation of Signal Transducer and Activator of Transcription 3 (p-STAT3), is being studied in psoriasis, the initial focus of our drug development efforts. Results from recently completed studies in patients showed improved efficacy and tolerability for the treatment of mild-to-moderate psoriasis.
While the drug development community has long sought a means to specifically inhibit p-STAT3, it had proven to be an elusive target until researchers at The University of Texas MD Anderson Cancer Center made several breakthrough discoveries. Moleculin licensed rights to the patents generated by MD Anderson, and developed formulations suitable for topical application in psoriatic patients.